Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Uptake of KRAS mutation testing in patients with metastatic colorectal cancer in Europe, Latin America and Asia.

Targeted oncology - 1 Sept 2011

Ciardiello Fortunato, Tejpar Sabine, Normanno Nicola, Mercadante Domenica, Teague Tracey, Wohlschlegel Bruno, Van Cutsem Eric

Abstract excerpt

The mutation status of the KRAS gene in the tumors of patients with metastatic colorectal cancer (mCRC) is a predictive biomarker for the efficacy of epidermal growth factor receptor monoclonal antibody therapy. The establishment of KRAS mutation testing in this setting represents a significant change to standard diagnostic procedures and a major advance in the personalization of cancer care. Against a changing...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Asia
Share to Cohort Studies

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Colorectal Neoplasms

Share to Europe

Share to Genes, ras

Share to Genetic Testing

Share to Latin America

Share to Practice Patterns, Physicians'

Source

Identifiers

PMID: 21630045
DOI: 10.1007/s11523-011-0181-x

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Uptake of KRAS mutation testing in patients with metastatic colorectal cancer in Europe, Latin America and Asia.PMID 21630045Read ↗

KRAS testing of patients with metastatic colorectal cancer in a community-based oncology setting: a retrospective database analysis.Semantic proximity Read ↗

Factors Associated With Guideline-recommended KRAS Testing in Colorectal Cancer Patients: A Population-based Study.Semantic proximity Read ↗

KRAS testing and epidermal growth factor receptor inhibitor treatment for colorectal cancer in community settings.Semantic proximity Read ↗

The KRAS mutation detection within the initial management of patients with metastatic colorectal cancer: a status report in France in 2011.Semantic proximity Read ↗

Assessing Oncologists' Adoption of Biomarker Testing in Metastatic Colorectal Cancer Using Real-World Data.Semantic proximity Read ↗

Biomarker testing and mutation prevalence in metastatic colorectal cancer patients in five European countries using a large oncology database.Semantic proximity Read ↗

Guideline-recommended incorporation of biomarker testing results in metastatic colorectal cancer therapy.Semantic proximity Read ↗

RAS mutation testing in patients with metastatic colorectal cancer in French clinical practice: A status report in 2014.Semantic proximity Read ↗

The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer.Semantic proximity Read ↗

Metastatic colorectal cancer treatment patterns according to kirsten rat sarcoma viral oncogene homolog genotype in U.S. Community-based oncology practices.Semantic proximity Read ↗

Performance and Cost Efficiency of KRAS Mutation Testing for Metastatic Colorectal Cancer in Routine Diagnosis: The MOKAECM Study, a Nationwide ExperienceSemantic proximity Read ↗

KRAS testing in metastatic colorectal cancer: implications on the use of biologic agents.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.